Orthofix Medical, Inc. (OFIX)

Orthofix Medical, Inc. (OFIX) stock has experienced a 52-week high of $20.73 and a 52-week low of $10.24. On August 5, 2025, Orthofix reported its second-quarter 2025 earnings, missing EPS estimates but surpassing revenue expectations. Insider trading activity has been observed, with President Massimo Calafiore purchasing stock in May and February 2025, and Engine Capital Management, LP also buying shares in February 2025; some insiders, including President Massimo Calafiore, sold shares earlier in the year. Product-related news included the global launch of the TrueLok Elevate Transverse Bone Transport System and the receipt of 510(k) clearance for the Fitbone Transport and Lengthening System and the Rodeo Telescopic Nail in July and May 2025, respectively. Analyst ratings have varied, with upgrades from Wall Street Zen and an "outperform" recommendation from Barrington Research, but a "sell" rating from Weiss Ratings; Stifel reinitiated coverage with a "Buy" rating and a price target of $22.

Information specifically detailing the demand seasonality for Orthofix Medical, Inc.'s products and services was not explicitly found. The broader orthopedic devices market is experiencing steady growth driven by factors such as the rising prevalence of musculoskeletal disorders, an aging global population, increasing incidence of sports and traumatic injuries, and technological advancements, suggesting a relatively stable and growing demand for orthopedic solutions rather than significant seasonal fluctuations.

Orthofix Medical, Inc. is a global medical technology company specializing in orthopedic and spine solutions, operating within the Health Care sector, specifically in the Medical/Dental Instruments industry. The company focuses on delivering reconstructive and regenerative musculoskeletal solutions, categorized into Global Spine and Global Orthopedics segments. The Global Spine segment offers bone growth stimulation devices, spine fixation and motion preservation implant products, biological products, and navigation technologies like the 7D FLASH™ Navigation System. The Global Orthopedics segment provides products and solutions for orthopedic conditions related to limb reconstruction and deformity correction, excluding the spine, including external and internal fixation orthopedic products.

Orthofix Medical, Inc. has a global presence, serving customers in numerous countries including the United States, Italy, Germany, the United Kingdom, France, and Brazil. The company maintains facilities and offices in locations such as Lewisville, Texas (headquarters), Carlsbad, California, Verona, Italy, Irvine, California, Toronto, Canada, Sunnyvale, California, Maidenhead, UK, Munich, Germany, Paris, France, and São Paulo, Brazil. Products are sold through direct sales teams and a network of distributors to hospitals, healthcare organizations, and healthcare providers worldwide.

No specific events explicitly impacting Orthofix Medical, Inc.'s brand reputation were found in the past year. The company's continuous efforts in product innovation, such as the global launch of the TrueLok Elevate Transverse Bone Transport System and regulatory clearances for new systems like Fitbone Transport and Lengthening System and Rodeo Telescopic Nail, generally contribute to a favorable perception. Orthofix emphasizes its commitment to advancing patient care through innovation and operational excellence.

Approximately 89.76% to 91.2% of Orthofix Medical, Inc.'s stock is held by institutional investors, including Engine Capital Management, LP, Rubric Capital Management LP, Paradigm Capital Management Inc/ny, BlackRock, Inc., Armistice Capital, Llc, Juniper Investment Company, LLC, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Dimensional Fund Advisors Lp. Engine Capital Management LP is the largest individual shareholder, holding 4.25 million shares, representing 10.77% of the company. Insider ownership is reported to be around 1.23%, 1.30%, 1.5%, or 12.64%, with key individual insiders including President Massimo Calafiore and Robert Gaines Cooper.